Aethlon Medical(US:AEMD) Newsfile·2024-06-03 13:05Core Insights - The global blood purification equipment market is projected to grow from USD 17,755.6 million in 2021 to USD 29,242.21 million by 2030, indicating significant market potential for companies in this sector [1]. Company Updates - Aethlon Medical, Inc. is advancing its Hemopurifier® device, which is designed to deplete cancer-promoting exosomes and circulating viruses. The FDA has designated it as a "Breakthrough Device" for treating advanced or metastatic cancer [3][4]. - Aethlon Medical is preparing for phase 1 clinical trials in Australia and India, targeting oncology patients with solid tumors who are not responding to anti-PD-1 monotherapy treatments like Keytruda® or Opdivo® [2][4]. - The company has integrated new in vitro data showing the Hemopurifier's ability to remove exosomes from cancer patient plasma into its clinical trial documentation, which is currently under review by Ethics Committees [2][4]. Financial Performance - CytoSorbents Corporation reported a 14% year-over-year increase in product sales for Q1 2024, reaching USD 9.0 million, the highest in nearly three years. The company also improved its product gross margins to 76% [5]. - Cerus Corporation reiterated its full-year 2024 product revenue guidance range of USD 172 million to USD 175 million, highlighting its ongoing progress in clinical milestones and commercial growth [6][7]. Industry Trends - The blood purification technology sector is gaining attention due to its potential applications in treating various diseases, including cancer and viral infections. Companies like Aethlon Medical are exploring the use of their devices in both oncology and viral disease treatments [11]. - The demand for innovative blood purification solutions is expected to rise, driven by global health challenges and the need for effective treatments against life-threatening conditions [11].